Acetyl Angiotensinogen (1-14), Porcine Mechanist

Acetyl Angiotensinogen (1-14), Porcine: Mechanistic Insights, Clinical Value, and Research Applications

Introduction (Product Overview, Mechanism of Action)
Acetyl Angiotensinogen (1-14), porcine, is a synthetic peptide derivative corresponding to the N-terminal 14 amino acids of porcine angiotensinogen, with an acetyl modification at the N-terminus. Angiotensinogen, a glycoprotein produced primarily by the liver, is the precursor of the renin-angiotensin system (RAS), a critical regulator of blood pressure, fluid balance, and electrolyte homeostasis (Fyhrquist & Saijonmaa, 2008, J Intern Med). The classical RAS cascade involves the enzymatic cleavage of angiotensinogen by renin to produce angiotensin I, which is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II is a potent vasoconstrictor and exerts multiple physiological and pathophysiological effects, including modulation of vascular tone, aldosterone secretion, and cellular proliferation (Paul et al., 2006, Physiol Rev).

Acetyl Angiotensinogen (1-14) represents a truncated and chemically modified fragment of the full-length angiotensinogen molecule. The acetylation at the N-terminus may enhance peptide stability, bioavailability, and resistance to proteolytic degradation, making it a valuable research tool for dissecting the molecular mechanisms of RAS and for developing novel therapeutic strategies targeting cardiovascular, renal, and metabolic disorders (Kokkonen et al., 1997, Biochem J). The porcine sequence is highly homologous to human angiotensinogen, facilitating translational research and comparative studies.

[Related: amanitin] Clinical Value and Applications
The clinical value of Acetyl Angiotensinogen (1-14), porcine, lies primarily in its utility as a research reagent for elucidating the structure-function relationships of angiotensinogen and its derivatives. By mimicking the N-terminal region of angiotensinogen, this peptide enables the investigation of substrate-enzyme interactions, particularly with renin and other proteases involved in RAS activation (Sealey et al., 2005, Hypertension). Furthermore, the acetylated form allows for the study of post-translational modifications and their impact on peptide function, receptor binding, and downstream signaling pathways.

In preclinical models, Acetyl Angiotensinogen (1-14) has been employed to:
- Characterize the kinetics of renin-mediated cleavage and the formation of angiotensin peptides.
- Investigate the role of N-terminal modifications in modulating angiotensinogen activity and stability.
- Serve as a substrate or inhibitor in enzymatic assays for drug screening and mechanistic studies.
- Explore the potential of peptide-based therapeutics targeting RAS components in hypertension, heart failure, and kidney disease.

[Related: Inhibitor of aminopeptidase N (APN)/CD13] Given the centrality of RAS in cardiovascular and renal pathophysiology, insights gained from studies utilizing Acetyl Angiotensinogen (1-14) may inform the development of next-generation therapeutics with improved efficacy and safety profiles.

Key Challenges and Pain Points Addressed
Current pharmacological interventions targeting the RAS, such as ACE inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors, have transformed the management of hypertension and related disorders. However, several challenges persist:
- Incomplete suppression of RAS activity due to compensatory mechanisms and alternative enzymatic pathways (Navar et al., 2011, Circ Res).
- Adverse effects, including cough, hyperkalemia, and renal dysfunction, associated with existing therapies.
- Limited understanding of the structural determinants governing angiotensinogen-renin interactions and substrate specificity.
- The need for robust, stable, and specific substrates for high-throughput screening of novel RAS modulators.

[Related: AM-2282] Acetyl Angiotensinogen (1-14), porcine, addresses these pain points by providing a chemically defined, stable, and functionally relevant peptide substrate. Its use facilitates detailed mechanistic studies, enables the identification of novel drug targets, and supports the rational design of peptide-based or small-molecule inhibitors with improved selectivity and reduced side effects.

Literature Review
A growing body of literature underscores the importance of angiotensinogen-derived peptides and their modifications in RAS research:

1. **Kokkonen et al. (1997, Biochem J)** demonstrated that N-terminal modifications of angiotensinogen, including acetylation, significantly influence the rate of renin cleavage and the generation of angiotensin I. Their findings highlight the utility of synthetic peptides in dissecting the enzymatic specificity of renin and the impact of post-translational modifications.

2. **Sealey et al. (2005, Hypertension)** reviewed the biochemical and clinical implications of angiotensinogen variants and their fragments, emphasizing the relevance of peptide substrates in understanding RAS regulation and in the development of diagnostic assays for renin activity.

3. **Paul et al. (2006, Physiol Rev)** provided a comprehensive overview of the RAS, including the structural and functional diversity of angiotensinogen-derived peptides. The review supports the use of synthetic fragments, such as Acetyl Angiotensinogen (1-14), in mechanistic and pharmacological studies.

4. **Fyhrquist & Saijonmaa (2008, J Intern Med)** discussed the clinical significance of RAS modulation and the potential for novel therapeutic approaches targeting upstream components, including angiotensinogen and its derivatives.

5. **Navar et al. (2011, Circ Res)** highlighted the limitations of current RAS inhibitors and the need for innovative strategies to achieve more complete and selective blockade of the system. The use of modified peptide substrates is proposed as a means to advance drug discovery and mechanistic research.

6. **Zhou et al. (2010, Peptides)** investigated the stability and bioactivity of acetylated angiotensin peptides, demonstrating enhanced resistance to proteolytic degradation and altered receptor binding profiles, supporting the rationale for N-terminal acetylation.

7. **Matsusaka et al. (2014, J Am Soc Nephrol)** explored the role of angiotensinogen in kidney disease and hypertension, underscoring the importance of precise molecular tools for studying RAS dynamics in vivo and in vitro.

Collectively, these studies validate the scientific utility of Acetyl Angiotensinogen (1-14), porcine, as a research tool and its potential translational relevance.

Experimental Data and Results
Experimental investigations employing Acetyl Angiotensinogen (1-14), porcine, have focused on its enzymatic properties, stability, and functional effects:

- **Enzymatic Cleavage:** Kokkonen et al. (1997) reported that acetylation of the N-terminus of angiotensinogen fragments modulates their susceptibility to renin cleavage. Acetyl Angiotensinogen (1-14) exhibits altered kinetic parameters (Km and Vmax) compared to unmodified peptides, providing insights into the determinants of substrate recognition and catalysis.

- **Stability Studies:** Zhou et al. (2010) demonstrated that N-terminal acetylation confers increased resistance to proteolytic degradation in plasma and tissue homogenates, extending the peptide’s half-life and facilitating its use in prolonged assays and in vivo studies.

- **Binding and Activity:** In vitro assays have shown that Acetyl Angiotensinogen (1-14) can serve as a competitive substrate or inhibitor in renin and ACE activity assays, enabling the quantification of enzyme kinetics and the screening of potential inhibitors (Sealey et al., 2005).

- **Functional Assays:** While the full physiological activity of the 1-14 fragment is distinct from that of angiotensin II, studies indicate that such peptides can modulate cellular signaling pathways, influence receptor interactions, and serve as probes for mapping functional domains within angiotensinogen (Paul et al., 2006).

These experimental findings support the use of Acetyl Angiotensinogen (1-14), porcine, as a robust and versatile tool for RAS research.

Usage Guidelines and Best Practices
To maximize the scientific value and reproducibility of experiments utilizing Acetyl Angiotensinogen (1-14), porcine, the following guidelines are recommended:

- **Preparation and Storage:** The peptide should be reconstituted in sterile, deionized water or appropriate buffer (e.g., phosphate-buffered saline) to the desired concentration. Aliquots should be stored at -20°C or below to prevent degradation. Avoid repeated freeze-thaw cycles.

- **Concentration and Dosage:** Optimal concentrations depend on the specific application (e.g., enzymatic assay, cell culture, in vivo administration). Typical working concentrations range from 1 μM to 100 μM. Pilot studies are advised to determine the dose-response relationship.< Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 53 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11533975